Affymax, Inc. is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. Our vision is to become a leader in the nephrology and specialty care space by delivering innovative therapeutic offerings to patients and healthcare providers.
- June 13, 2014 Affymax and Takeda Announce Termination of Omontys®(peginesatide) Product Collaboration and License Agreement
- Nov 26, 2014 Affymax, Inc. Announces a Special Cash Distribution And The Appointment Of a New Director And Chief Executive Officer
- Nov 26, 2014 Affymax Adopts Tax Benefit Preservation Plan to Protect Net Operating Loss Carryforwards
Computershare Trust Company, Inc.
350 Indiana Street, Suite 800, Golden, Colorado 80401